

For Immediate Release

Contacts:

Krista Conway, Trendy Media Group

740-281-8378

krista@trendymediagroup.com

Eric Langer, BioPlan Associates, Inc.

301-921-5979

elanger@bioplanassociates.com

Biopharm Budgets up for Process Development and Downstream Technologies in 2010, According to New Report

Recent Study Provides Analysis of Worldwide Biomanufacturing

May 2009 (Rockville, MD) – This year severe constraints on global financial markets have hit most biomanufacturing budgets, with most operations, such as new facility budgets hit hardest. BioPlan’s “6th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production,” indicates an average 6% decrease in new facilities.

However, the newly released report also indicates areas where budgets are increasing, including process development and downstream technology. The analysis of worldwide biomanufacturing includes data from 446 biopharmaceutical developers & contract manufacturing organizations from 35 countries.

Capacity Expansion Plans


Despite the average reduction in budgets, nearly 30% of all respondents expect to at least double their total production capacity over the next five years (by 2013), a jump from 22% last year.

“A major factor impacting production capacity expansion over the next five years will be the need for improved downstream purification performance,” according to Eric Langer, president and managing partner at BioPlan Associates. “In fact, the factor most likely to constrain production capacity over the next five years is downstream purification equipment, indicated by 30.5% of respondents.” With downstream purification issues clearly recognized as the current bottleneck, it is not surprising to find this factor one of the top issues where budgets will *increase* this year.

The report also found that, among CMO respondents, the need for downstream improvements was an even greater factor than for the drug innovators (downstream bottlenecks were indicated as a major capacity constraint by 48% of CMO’s compared with 27% of drug innovators).

This year’s report coverage includes analysis of biomanufacturers’ experiences in the US, Western Europe and other regions in the following areas:

- Capacity, production, and outsourcing
- Budget changes



- Use of Expression Systems
- Downstream purification problems and issues
- Current industry bottlenecks
- Capacity utilization and current production levels
- How capacity bottlenecks are being resolved
- Projected capacity bottlenecks
- Production trends and implications for industry
- Outsourcing trends
- Disposables: Spending growth; applications; reasons for increasing/ restricting use; budgets; vendor satisfaction
- Range of titres in biomanufacturing
- Batch failure rates
- Selecting a CMO
- PAT implementation issues
- Automation implementation
- Quality manufacturing issues
- Hiring and employment growth
- Cold chain management
- Industry supplier growth rates

Capacity Utilization

“Over the past three years, the percent of operating capacity at which respondents’ facilities are operating has declined by 3% annually for both mammalian cell culture systems, and microbial fermentation.” notes Langer. “Overall capacity utilization is currently at 63.3% for mammalian systems, and 55.3% for microbial fermentation. Capacity utilization has been particularly weak for US manufacturers using microbial fermentation systems, with nearly a 10 percentage point difference between the US and Western Europe.”

About BioPlan

BioPlan Associates, Inc., is a life sciences market research and publishing organization and has provided market studies and research to biopharmaceutical, biotechnology, and healthcare companies since 1989. For more information about BioPlan Associates, Inc., please visit our website at <http://www.bioplanassociates.com>.

Please call 301-921-5979 to arrange interviews with Eric Langer or for graphics related to this report and data.

###